Ozempic (GLP-1) Lawsuit — Free Case Review
Which Medications — and Which Injuries — Qualify
Eligibility differs by drug and by injury track. Check yours against the current criteria in minutes.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Did this happen to you — or someone you love?
Answered 24/7 · Free & confidential · No fee unless there is a recovery. Court costs and litigation expenses are advanced by counsel and repaid from the recovery. You are not responsible for court costs or litigation expenses if there is no recovery, unless a court directs otherwise. The attorney's fee is a percentage of the gross recovery, calculated before expenses are deducted.
Partners
Matthew T. Marin & Stefanie A. Murphy
Super Lawyers® honorees · American Association for Justice members
Ozempic inquiries get a personal review — and an honest answer either way, free and without obligation.
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone's injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state. Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber. Attorney Advertising.
Every FAERS number we publish — on the by-injury data page, the tracker, and elsewhere — comes from the FDA’s public openFDA API, using the exact queries documented on this page. Anyone with a browser can reproduce our counts in about a minute. This page explains how we count, what the numbers can and cannot tell you, and when we update them.
The data source
The FDA Adverse Event Reporting System (FAERS) is the FDA’s database of adverse-event and medication-error reports submitted by manufacturers (who are legally required to forward reports they receive), health-care professionals, and patients. The FDA publishes it through the openFDA drug/event API (api.fda.gov), refreshed roughly quarterly. Our current counts use the FDA’s July 30, 2026 data release; the as-of date is printed beside every table we publish.
How we count
We count unique reports, per medication, per reaction term:
- Medication: reports where the drug’s generic name matches, via
patient.drug.openfda.generic_name— “semaglutide” covers Ozempic, Wegovy, and Rybelsus; “tirzepatide” covers Mounjaro and Zepbound; “dulaglutide” covers Trulicity. This captures the drug named in the report in any role (suspect or concomitant). - Injury: reactions are coded in FAERS using MedDRA preferred terms. We count exact preferred-term matches via the API’s term-count facility (
count=patient.reaction.reactionmeddrapt.exact) — so “Ileus” counts only reports coded with that exact preferred term, not free-text mentions. NAION appears in MedDRA as “Optic ischaemic neuropathy,” and gastroparesis appears as “Impaired gastric emptying” — in the openFDA dataset, a query for the literal term “Gastroparesis” returns almost nothing, a trap that quietly zeroes out the most important number in this litigation. We verified the term mapping against the reaction-term distributions of each drug before publishing a single count. - Severity: “serious” uses the FDA’s own
serious:1flag (death, life-threatening event, hospitalization, disability, or similar); death outcomes useseriousnessdeath:1.
Example — the exact query behind one cell of our table (paste into a browser):
https://api.fda.gov/drug/event.json?search=patient.drug.openfda.generic_name:"semaglutide"&count=patient.reaction.reactionmeddrapt.exact&limit=1000
That call returns every reaction term reported with semaglutide and its count; our table reads the rows for the injury terms at issue in the litigation.
What these numbers are not
- Not proven injuries. Reports are unverified. The FDA states plainly that a FAERS report does not establish that the drug caused the event.
- Not a rate. There is no denominator. Millions of people take GLP-1 medications; raw counts cannot be converted into risk without exposure data these numbers do not contain.
- Not immune to bias. Reporting rises with media coverage, label changes, and litigation itself (lawyer-submitted reports are part of FAERS). Newer drugs accumulate reports on a different curve than older ones.
- Not duplicate-free. The FDA deduplicates imperfectly; the same event can appear more than once.
- Not a substitute for the courts’ evidence standards. The MDL requires objective diagnostic confirmation for gastroparesis claims — a FAERS report would not qualify anyone.
What they are good for — and why regulators use them the same way: detecting which adverse events are being reported and in what relative pattern across drugs of the same class. That signal-detection role is exactly how the possible NAION association surfaced before it reached European labels.
Update cadence and corrections
We re-run every query after each quarterly FDA data release and update the published tables, noting the new as-of date. If a count changes materially between releases — including downward, which happens when the FDA removes duplicates — we publish the new number without ceremony. If you find an error, tell us; we will check the query and correct the page.
Free, confidential case review. Marin & Murphy is currently accepting Ozempic (GLP-1) stomach-injury and NAION vision-loss cases. No fee unless there is a recovery. Marin & Murphy is licensed in Rhode Island, Connecticut, Massachusetts, and South Carolina; matters elsewhere may be referred to lawyers licensed in your state.
Start your free case review or call (888) 348-2735 — answered 24/7.
Common questions
Why do your numbers differ from other websites’?
Usually one of four reasons: a different data release date, brand-name versus generic-name matching, counting free-text mentions instead of exact MedDRA terms, or the term-spelling trap described above (a “Gastroparesis” query that silently returns near-zero). Our queries are published above precisely so the differences can be checked rather than argued about.
Can I look up my own report?
Individual reports are public but anonymized. The FDA’s public FAERS dashboard allows case-level browsing; the API queries above return the same underlying data.
Does the FDA endorse these counts?
No — and the FDA’s own disclaimer applies: openFDA data should not be used to make medical decisions, and results should be treated as unvalidated. We publish the queries so the counting itself is beyond dispute; the interpretation limits are described above.
Sources
- openFDA drug/event API documentation, api.fda.gov (searchable fields and count facility)
- FDA, “Questions and Answers on FDA’s Adverse Event Reporting System (FAERS)”
- FDA openFDA data release July 30, 2026 (the as-of date for all published counts)
No Ozempic or other GLP-1 lawsuit has been settled, and no court or jury has found that these medications caused anyone’s injury — the litigation is ongoing, with major expert-evidence rulings still ahead. Whether any individual has a claim depends on their own medical records and the law of their state.
Do not stop, start, or change any prescribed medication because of anything on this page. Those decisions belong with your prescriber.
Attorney Advertising.
This page is attorney advertising and is for informational purposes only; it is not legal or medical advice. Prior results do not guarantee a similar outcome. Contacting the firm does not create an attorney-client relationship.
The data: FDA adverse-event data, FAERS reports by injury, the US vs. EU warning-label gap, and the lawsuit tracker.